Trials of Safety and Efficacy There is now extensive research concerning the efficacy and general safety of the first four DPP-4 inhibitors: sitagliptin, linagliptin, vildagliptin and saxagliptin
Wong ML, Inserra A, Lewis MD, Mastronardi CA, Leong L, Choo J, et al
GHK-Cu activates Wnt/-catenin signaling , encouraging stem cell proliferation and follicle cycling
Strengths and Limitations Strengths of our consensus report and the associated recommendations include the participation of an international panel of experts in GLP-1 and GLP-1/GIP RA therapies from the United States, Europe, and Asia, along with participation of individuals with lived experience of T1D and using GLP-1 and GLP-1/GIP RA therapy